Kezar Life Sciences, Inc. (NASDAQ:KZR) Q2 2020 Earnings Conference Call - Final Transcript

Aug 05, 2020 • 04:30 pm ET

Previous

Kezar Life Sciences, Inc. (NASDAQ:KZR) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Operator
Operator

[Operator Instructions] Our first question is coming from Maury Raycroft of Jefferies, please go ahead.

Analyst
Kazeem

This is Kazeem [Phonetic] on for Maury. Can you help us understand better what factors predominantly contributed to better tolerability on Cohort 2c? Was it the -- lyophilized formulation like the triple dosing on the [Indecipherable]?

Executive
Noreen R. Henig

Hi, Maury, this is Noreen. I'm happy to take that question. The better tolerability was seen to be through a combination of factors. First, we had moved from a frozen solution to a lyophilized formulation of KZR-616. Second is we used a step-up dosing where patients received 30 milligrams the first week and then the target dose thereafter. And lastly, we introduced a number of supportive measures of suggestions to patients and physicians to help them feel comfortable with this new drug. These kind of pre-dose suggestions are relatively light touch, including oral hydration or non-sedating antihistamine, and then all of those measures together contributed to the increased tolerability.

Analyst
Kazeem

Okay. To the new formulation, does this basically make the drug more stable or what is special about it?

Executive
Christopher Kirk

Hi, I can answer that. It does not change the stability of KZR-616. What it does is remove one of the excipients that was used in the initial formulation, an agent called polysorbate 80. That while enhancing solubility does come with the potential for adverse drug reactions and so to simplify the formulation in order to move into a life formulation, and ultimately, patient self-administration. We went to this next generation formulation that we're currently using.

Analyst
Kazeem

That's great. Thank you. One final question is, in the Cohort 2c are there any more lupus nephritis patients.

Executive
Noreen R. Henig

Sorry, can you repeat the question?

Analyst
Kazeem

In Cohort 2c are there any more lupus nephritis patients?

Executive
Noreen R. Henig

No, there are not any more lupus nephritis patients in the Cohort 2c.

Analyst
Kazeem

Thank you so much.

Operator
Operator

Thank you. Our next question is coming from Ram Selvaraju of H.C. Wainwright. Please go ahead.

Analyst
Blair Cohen

Hi, this is Blair Cohen on for Ram, just a couple coming from me. When do you think we could expect another update from the Stage 1b MISSION study and how many patients do you think we should expect in that data? Has the progression of the trial been impacted by COVID-19 at all? Any update on that?

Executive
Noreen R. Henig

Hello. So I think that our goal is to be able to provide an interim update by the end of this year, as we believe we will have fully enrolled our third and final cohort this month, and therefore we should have at least some initial interim data by the end with a follow-up phase to come in the first half of 2021.

Analyst
Blair Cohen

Okay, great. To what extent would you say the PRESIDIO timeline has been impacted by COVID-19? Do you expect any issues with the integrity of the data?

Executive
Noreen R. Henig

Two good questions. So the PRESIDIO is enrolling a very rare disease patient population and there definitely has been some slowing of enrollment in the PRESIDIO trial. So we had